Challenging Conventional Perceptions of Oncogenes and Tumor Suppressor Genes: A Comprehensive Analysis of Gene Expression Patterns in Cancer
Genes, Chromosomes and Cancer · 2025
DOI: 10.1002/gcc.70030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, Chromosomes and Cancer, 2025. Verfasst von Mingyuan Zou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disea…. Hauptthemen laut MEDLINE: Oncogenes, Neoplasms, Genes, Tumor Suppressor, Gene Expression Regulation, Neoplastic. Die Arbeit nennt 31 Literaturangaben. Gefördert von: the Postdoctoral Fellowship Program of CPSF, Guangdong Basic and Applied Basic Research Foundation of China, the National Natural Science Foundation of China.
Abstract (Originalsprache)
Identifying genes involved in cancer is crucial for understanding the underlying molecular mechanisms of the disease and developing effective treatment strategies. Differential expression analysis (DEA) is the predominant method used to identify cancer‐related genes. This approach involves comparing gene expression levels between different samples, such as cancerous and non‐cancerous tissues, to identify genes that are significantly upregulated or downregulated in cancer. DEA is based on the commonly believed assumption that genes upregulated in cancerous tissues have the potential to function as oncogenes. Their expression levels often correlate with cancer advancement and unfavorable prognosis, whereas downregulated genes display the opposite correlation. However, contrary to the prevailing belief, our analysis utilizing The Cancer Genome Atlas (TCGA) databases revealed that the upregulated or downregulated genes in cancer do not always align with cancer progression or prognosis. These findings emphasize the need for alternative approaches for identifying cancer‐related genes that may be more accurate and effective. To address this need, we compared the effectiveness of machine learning (ML) methods with that of traditional DEA in the identification of cancer‐related genes. ML algorithms have the advantage of being able to analyze large‐scale genomic data and identify complex patterns that may go unnoticed by traditional methods. Our results demonstrated that ML methods significantly outperformed DEA in the screening of cancer‐related genes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangz…
- Medical School, Guangzhou Medical University, Guangzhou, People's Republic of China.
- Department of Clinical Laboratory, Zhuhai, People's Republic of China.
ORCID-Profile: Mingyuan Zou
Förderung
- the Postdoctoral Fellowship Program of CPSF
- Guangdong Basic and Applied Basic Research Foundation of China
- the National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Zou, M., Qiu, L., Wu, W., Liu, H., Xiao, H., & Liu, J. (2025). Challenging Conventional Perceptions of Oncogenes and Tumor Suppressor Genes: A Comprehensive Analysis of Gene Expression Patterns in Cancer. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.70030
Vancouver
Zou M, Qiu L, Wu W, Liu H, Xiao H, Liu J. Challenging Conventional Perceptions of Oncogenes and Tumor Suppressor Genes: A Comprehensive Analysis of Gene Expression Patterns in Cancer. Genes, Chromosomes and Cancer. 2025. doi:10.1002/gcc.70030
BibTeX
@article{Zou2025,
author = {Zou, Mingyuan and Qiu, Li and Wu, Wentao and Liu, Hui and Xiao, Han and Liu, Jun},
title = {Challenging Conventional Perceptions of Oncogenes and Tumor Suppressor Genes: A Comprehensive Analysis of Gene Expression Patterns in Cancer},
journal = {Genes, Chromosomes and Cancer},
year = {2025},
doi = {10.1002/gcc.70030}
}
EUVIMED